XLO — XILIO THERAPEUTICS INC
什么是 13F 持仓报告?谁需要申报、何时申报 · 13F 持仓报告看不到什么
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
截至Q2 2026,共 27 家机构在其最新 13F 申报中持有 XLO(XILIO THERAPEUTICS INC),合计申报市值 $32.89M,对应 3.43M 股。按股数计算较上季度增持 9.2%(+219.33K 股),申报市值环比上升 24.4%。持仓集中度较高:前五大持有人占申报市值的 74.4%,前十大的集中度为 92.3%。
与上一季度相比,12 家新建仓位、4 家加仓、4 家减仓、9 家清仓退出。13F 数据为季末快照,以上变动反映的是 Q2 2026 末的持仓状态,并非实时交易。
XILIO THERAPEUTICS INC(XLO)的主要机构持有人包括 Bain Capital Life Sciences Investors, LLC、GILEAD SCIENCES, INC.、ORBIMED ADVISORS LLC,按 13F 申报市值在本页 94 家持有人中排名居前。
XLO 属于Health Care板块。
本页所有数据均来自美国证监会(SEC)13F 季度申报。13F 申报人需在季度结束后 45 天内披露 10 万美元以上的多头持仓;空头、期权对冲与季度内交易不在其列,因此这些数字反映的是机构持仓的季度快照,而非实时仓位。
机构逐季持仓趋势
| 季度 | 持有机构数 | 股数 | 金额 | 环比净变动 |
|---|---|---|---|---|
| Q3 2026 | 17 | 1.37M | $12.42M | -0.8% |
| Q2 2026 | 27 | 3.43M | $32.89M | +9.2% |
| Q1 2026 | 24 | 2.62M | $22.03M | -92.3% |
| Q4 2025 | 37 | 39.73M | $25.43M | +13.9% |
| Q3 2025 | 35 | 20.58M | $17.37M | -1.6% |
| Q2 2025 | 34 | 22.32M | $15.18M | -1.1% |
| Q1 2025 | 35 | 21.10M | $15.29M | -1.4% |
| Q4 2024 | 34 | 24.38M | $23.27M | -1.4% |
表内 8 个季度中,机构持股合计减少 94%(Q4 2024 → Q3 2026);单季变动最大的是 Q1 2026(-92.3%)。
前 25 大机构持仓人(Q3 2026) — 17 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 650.39K | $5.89M | 0.40% | 持有 | |
| 198.18K | $1.79M | 0.00% | 增持 | |
| 189.09K | $1.71M | 1.31% | 减持 | |
| 105.98K | $959.14K | 0.12% | 持有 | |
| 63.55K | $575.15K | 0.00% | 减持 | |
| 53.67K | $485.75K | 0.00% | 减持 | |
| 41.45K | $375.14K | 0.00% | 增持 | |
| 28.19K | $255.15K | 0.00% | 增持 | |
| 13.31K | $120.47K | 0.00% | 持有 | |
| 12.45K | $112.00K | 0.00% | 新进 | |
| 10.91K | $98.72K | 0.00% | 增持 | |
| 3.36K | $30.40K | 0.00% | 新进 | |
| 714 | $6.46K | 0.00% | 持有 | |
| 544 | $4.92K | 0.00% | 增持 | |
| 59 | $534 | 0.00% | 持有 | |
| 58 | $524 | 0.00% | 增持 | |
| 1 | $9 | 0.00% | 新进 |
更早季度的机构持仓记录(逐季列表): 返回前 25 大机构持仓人
Q2 2026 — 25 家基金
Q1 2026 — 24 家基金
Q4 2025 — 25 家基金
Q3 2025 — 25 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 9.11M | $7.67M | 0.43% | 持有 | |
| 4.57M | $3.85M | 0.26% | 持有 | |
| 1.48M | $1.25M | 0.55% | 持有 | |
| 1.26M | $1.06M | 0.00% | 增持 | |
| 961.92K | $810.61K | 0.00% | 减持 | |
| 667.74K | $595.56K | 0.52% | 持有 | |
| 511.82K | $431.31K | 0.00% | 持有 | |
| 328.97K | $277.26K | 0.00% | 减持 | |
| 328.79K | $277.07K | 0.00% | 增持 | |
| 249.63K | $210.44K | 0.03% | 持有 | |
| 204.70K | $172.50K | 0.00% | 增持 | |
| 198.86K | $167.58K | 0.00% | 持有 | |
| 163.89K | $138.11K | 0.00% | 增持 | |
| 87.79K | $73.98K | 0.00% | 增持 | |
| 76.05K | $64.08K | 0.00% | 增持 | |
| 66.61K | $56.13K | 0.00% | 持有 | |
| 56.08K | $47.26K | 0.00% | 持有 | |
| 32.13K | $27.08K | 0.00% | 新进 | |
| 31.00K | $26.12K | 0.00% | 持有 | |
| 29.69K | $25.02K | 0.00% | 新进 | |
| 25.00K | $21.07K | 0.00% | 持有 | |
| 25.00K | $21.07K | 0.00% | 持有 | |
| 24.74K | $20.00K | 0.00% | 新进 | |
| 25.00K | $19.33K | 0.00% | 持有 | |
| 18.76K | $15.81K | 0.00% | 持有 |
Q2 2025 — 25 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 9.11M | $6.19M | 0.48% | 持有 | |
| 4.57M | $3.10M | 0.39% | 持有 | |
| 1.48M | $1.01M | 0.47% | 持有 | |
| 1.44M | $982.00K | 0.00% | 增持 | |
| 1.33M | $906.31K | 0.03% | 新进 | |
| 1.15M | $782.70K | 0.00% | 增持 | |
| 667.74K | $454.00K | 0.49% | 持有 | |
| 511.82K | $347.99K | 0.00% | 减持 | |
| 369.66K | $251.35K | 0.00% | 减持 | |
| 249.63K | $169.75K | 0.03% | 持有 | |
| 239.97K | $163.18K | 0.00% | 增持 | |
| 235.46K | $160.09K | 0.00% | 新进 | |
| 198.86K | $135.20K | 0.00% | 减持 | |
| 164.20K | $111.64K | 0.00% | 减持 | |
| 142.34K | $96.78K | 0.00% | 减持 | |
| 78.03K | $53.05K | 0.00% | 减持 | |
| 66.61K | $45.29K | 0.00% | 持有 | |
| 56.08K | $38.13K | 0.00% | 减持 | |
| 43.39K | $29.50K | 0.00% | 持有 | |
| 34.72K | $23.61K | 0.00% | 新进 | |
| 31.00K | $21.08K | 0.00% | 新进 | |
| 25.00K | $17.50K | 0.00% | 减持 | |
| 25.00K | $17.00K | 0.00% | 减持 | |
| 25.00K | $17.00K | 0.00% | 持有 | |
| 18.76K | $12.76K | 0.00% | 减持 |
新建仓(Q2 2026)
- ORBIMED ADVISORS LLC 592.30K 股 · $5.67M
- ADAGE CAPITAL PARTNERS GP, L.L.C. 111.54K 股 · $1.07M
- GEODE CAPITAL MANAGEMENT, LLC 39.05K 股 · $374.17K
- Citadel Advisors 25.95K 股 · $248.60K
- BRIDGEWAY CAPITAL MANAGEMENT, LLC 17.54K 股 · $168.07K
- Two Sigma Investments 14.54K 股 · $139.33K
- PRELUDE CAPITAL MANAGEMENT, LLC 11.60K 股 · $111.13K
- BlackRock Inc 8.76K 股 · $83.89K
- Steward Partners Investment Advisory, LLC 714 股 · $6.84K
- SECURITY NATIONAL BANK OF SIOUX CITY IOWA /IA/ 321 股 · $3.08K
- BARCLAYS PLC 115 股 · $1.10K
- JONES FINANCIAL COMPANIES LLLP 29 股 · $262
完全清仓(较上季)
- Caligan Partners LP 卖出 112.13K 股 · $943.00K
- AJU IB Investment Co., Ltd. 卖出 47.70K 股 · $401.12K
- Fidelity Management & Research (FMR) 卖出 36.56K 股 · $307.45K
- Ghisallo Capital Management LLC 卖出 13.80K 股 · $116.06K
- STATE STREET CORP 卖出 13.31K 股 · $111.95K
- CWM, LLC 卖出 4.21K 股 · $35.37K
- JPMorgan Chase & Co 卖出 240 股 · $1.98K
- Vanguard Global Advisers, LLC 卖出 210 股 · $1.77K
- ROYAL BANK OF CANADA 卖出 91 股 · $1.00K
基金持仓历史 — 各季度股数(前 20 只基金)
| 基金 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 650.39K | 650.39K | 650.39K | 9.11M | 9.11M | 9.11M | 9.11M | 9.11M | — | — | — | — | — | — | — | — | — | — | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 198.18K | 178.52K | 123.66K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stonepine Capital Management, LLC | 189.09K | 225.99K | 64.16K | 126.27K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Merck & Co., Inc. | 105.98K | 105.98K | 105.98K | 1.48M | 1.48M | 1.48M | 1.48M | 1.48M | — | — | — | — | — | — | — | — | — | — | — | — |
| Renaissance Technologies | 63.55K | 64.15K | 49.57K | 344.42K | 204.70K | 164.20K | 177.70K | 296.62K | 266.30K | 295.00K | 249.45K | 209.70K | 20.70K | 20.30K | 18.80K | 37.10K | 28.50K | 75.30K | — | — |
| Morgan Stanley | 53.67K | 56.95K | 57.49K | 839.85K | 961.92K | 1.44M | 1.16M | 1.00M | 1.52M | 1.11M | 221.91K | 127.27K | 26.27K | 27.02K | 30.54K | 25.61K | 6.84K | 7.04K | 2.10K | 1.04K |
| Geode Capital Management | 41.45K | 39.05K | 37.20K | 328.97K | 328.97K | 369.66K | 379.02K | 358.42K | 338.19K | 182.85K | 84.83K | 84.83K | 84.83K | 84.73K | 84.73K | 84.73K | 83.59K | 83.59K | 141.71K | 134.19K |
| VANGUARD FIDUCIARY TRUST CO | 28.19K | 22.59K | 28.48K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| STATE STREET CORP | 13.31K | — | 13.31K | 186.39K | 163.89K | 43.39K | 43.39K | 43.39K | 43.39K | 43.39K | 15.69K | 15.69K | 15.69K | — | — | — | — | — | — | — |
| HRT FINANCIAL LP | 12.45K | — | — | 31.89K | 24.74K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| BlackRock Inc | 10.91K | 8.76K | — | 2.04K | 2.04K | 2.04K | 74.70K | 76.09K | 75.62K | — | — | — | — | — | — | — | — | — | — | — |
| Vanguard Global Advisers, LLC | 3.36K | — | 210 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Steward Partners Investment Advisory, LLC | 714 | 714 | — | — | — | — | 20.00K | 20.00K | 20.00K | — | — | — | — | — | — | — | — | — | — | — |
| UBS Group AG | 544 | 14 | 4.04K | 203 | 13.65K | 239.97K | 163.10K | 249.40K | 15.73K | 201 | 201 | 201 | 201 | 201 | 201 | 201 | 201 | 2.81K | 964 | 3.98K |
| Key FInancial Inc | 59 | 59 | 59 | 830 | 830 | 830 | 830 | 830 | 830 | 830 | 830 | 830 | 830 | — | — | — | — | — | — | — |
| JONES FINANCIAL COMPANIES LLLP | 58 | 29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Citigroup Inc | 1 | — | — | — | 258 | — | — | — | — | — | — | — | — | — | — | — | — | 67 | 323 | 2.19K |
| Bain Capital Life Sciences Investors, LLC | — | 664.02K | 664.02K | 7.37M | 4.57M | 4.57M | 4.57M | 4.57M | 4.57M | 3.79M | 2.81M | 2.81M | 2.81M | — | — | — | — | — | — | — |
| Atlas Venture Life Science Advisors, LLC | — | — | — | — | — | — | — | — | — | — | 992.91K | 2.76M | 2.76M | — | — | — | — | — | — | — |
| ORBIMED ADVISORS LLC | — | 592.30K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
▲ 低买(基金新建/增持,下一季股价上涨 ≥5%) ▼ 高卖(基金减持,下一季股价下跌 ≥5%)
拖拽/滚轮缩放 · 默认显示最近一年 · 标注来自 13F 申报中的季度基金操作 · 悬停查看详情
常见问题
Which funds hold XLO?
As of 2026-Q2, 27 institutional funds reported holding XLO (XILIO THERAPEUTICS INC) in SEC 13F filings, with a combined reported value of $32.89M.
How many shares of XLO do institutions own?
13F filers reported 3.43M shares of XLO, worth $32.89M in aggregate at the end of 2026-Q2.
Is institutional ownership of XLO rising or falling?
Share counts moved +9.2% versus the prior quarter — accumulation.
Who are the top institutional holders of XLO?
The largest 13F holders are Bain Capital Life Sciences Investors, LLC, GILEAD SCIENCES, INC., ORBIMED ADVISORS LLC, Frazier Life Sciences Management, L.P., Rock Springs Capital Management LP; the top 25 are ranked at the top of this page.
Who are the major shareholders of XILIO THERAPEUTICS INC?
The major shareholders of XILIO THERAPEUTICS INC (XLO) by reported 13F value are Bain Capital Life Sciences Investors, LLC, GILEAD SCIENCES, INC., ORBIMED ADVISORS LLC, Frazier Life Sciences Management, L.P., Rock Springs Capital Management LP, among 94 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.